Strong growth masked by margin compression and cost headwinds
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met H1 growth expectations (89.7% YoY vs 71.7% claimed). Reaffirmed FY28 >₹1,600 Cr (raised prior ₹1,500 Cr). But cut EBITDA margin aspiration (24% → 20-21%).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue momentum (90% YoY) backed by 62% volume growth and new capacity. But Q2 delivered margin compression (300 bps QoQ), QoQ PAT decline of 6.6%, and management downgraded EBITDA aspiration from 24% to 20-21%. Freight and energy cost headwinds unresolved; analyst pressure on how 66% utilization coexists with 40% growth suggests execution stress. Long-term contract and capex expansion are credible catalysts, but near-term execution risk is material.
₹347.7 Cr
Revenue · +89.7% YoY₹33.7 Cr
Reported PAT · +593.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
62% volume growth YoY, 7% QoQ
METRevenue growth 89.7% YoY, 13% QoQ implies ~17% pricing contribution YoY
Capacity utilization 66% in Q2, up from 60% in Q4 FY26
METNo conflicting data; context shows 6ppt growth in utilization despite 40% revenue growth (suggests product mix shift, new customer onboarding capacity constraints)
Maintain 24% EBITDA margin going forward
MISSManagement now targets 20%-21% EBITDA margin, explicit downgrade under cost pressure
Export 70% of revenue in Q2 FY27
METManagement confirmed in Q&A: Q1 FY27 ~65%, Q2 FY27 ~70%
Freight cost impact ₹20 Cr in Q2 vs ₹10 Cr in Q1
METDisclosed in CFO remarks; additional headwind of ₹1.8 Cr from gas prices
Earnings quality
What changed since the last call
EBITDA margin aspiration downgraded
DowngradePrior 'maintain 24% EBITDA margin'; now 'target 20%-21% or more than that, but that's our aspiration'. Cost headwinds (freight ₹20 Cr Q2, energy, logistics delays) and new product ramp-up margin dilution cited as drivers.
FY27 capex raised
Upgrade₹125 Cr (prior) → ₹250 Cr (now) for two Pakhajan manufacturing buildings. Incremental commitment reflects customer demand and long-term contract expectations.
FY28 revenue guidance reaffirmed
Neutral>₹1,600 Cr (no change from Q1 call). Management reaffirms but hedges further: 'We are positive even today, but I don't want to commit anything more. Very clear, it will be more than 1,600.'
New long-term customer contract disclosed
NewMNC supply agreement ₹150 Crores order book; ₹120 Cr received to date; trial Q4 FY27, commercialization Q1 FY28. Expected to contribute multi-year growth.
The Q&A
Analysts pressed hard on capacity utilization lag (only 66% despite 40% growth target), margin compression (300 bps Q-o-Q), cost pass-through inability, and EBITDA margin downgrade. Management held but hedged heavily: acknowledged cost challenges are 'temporary', reaffirmed '>₹1,600 Cr' but without precision, refused to commit to 24% EBITDA ('too difficult in current situation'). Q&A revealed caution, not confidence.
Revenue growth vs utilization mismatch — Lovish Soien, Burman Capital Management
PartialVolume 7% QoQ, utilization Q4 to Q2 from 60% to 66%. Pricing up 10-15%. Product mix shift to new higher-margin products. New customer onboarding absorbed extra capacity. Explains utilization lag.
MNC contract scope and materiality — Aman Vij, Asutec Investment Management
DodgedNDA prevents customer name disclosure. Multiple products involved. 'One of the big MNC, you're talking about other four, I don't know about other four.' Cannot divert information.
EBITDA margin maintenance — Umesh Gupta, AlphaOptimus PMS
Answered20% will be lower side. Anything above that could be guess. Margin shrunk due to freight and energy. 'I cannot assure that we will achieve 24% or I will achieve 25%.' Too difficult in current situation. Aspiring to go down — passing benefit to customer.
Margin decline drivers — Darshil Jhaveri, Crown Capital
PartialWorking hard to maintain margin. Demand growing. Reaching existing and new customers with pricing band. In short term, no challenge. Export market raw material costs volatile. Need caution on cost pass-through.
Phase 2 capex and customer-backed utilization — Lovish Soien, Burman Capital Management
AnsweredSoft commitment from customer. About 50% of total utilization. Mix of existing and new customers onboarded. Confidence to put capex based on existing order visibility.
Export market opportunity and localization strategy — Lovish Soien, Burman Capital Management
AnsweredYes, inquiries on localization. 'Sizeable opportunity.' Local Indian product sourced. Part of the growth strategy, part of the ₹250 Crores incremental, not all.
FY28 revenue guidance conservatism — Kanav Garg, Garg Advisors
PartialBetter to be conservative than optimistic. Will be happy if cross target. If don't cross, will ask what went wrong. '>₹1,600 Cr' without absolute commitment. Very clear, it will be more than 1,600.
Business model diversification and customization — Gulam Soni, Individual Investor
PartialR&D team works on different projects including lubricant and other industrial applications. Focus will be leveraging chemistry expertise. Beyond FY28 targeting ₹1,600 Crores. Further strategy given at end-27 call.
Guidance
FY28 revenue >₹1,600 Crores
MediumReaffirmed from Q1 call (prior ₹1,500 Cr). Backed by ₹150 Cr MNC contract (trial Q4 FY27, launch Q1 FY28) and capex expansion. But >₹1,600 is vague, not a specific target. Management hedged: 'Very clear, it will be more than 1,600.'
EBITDA margin 20%-21% (down from 24% prior)
LowManagement says '20% will be the lower side.' But cannot commit to 24% or higher. Cost headwinds (freight, energy, logistics delays) cited. Aspirational target, not committed.
FY27 capex ₹250 Crores (raised from ₹125 Cr)
HighTwo manufacturing buildings at Pakhajan. Building 1 & 2 to ramp H2 FY27 / Q1 FY28. Building 3 & 4 operational by Q4 FY28 / Q1 FY29. Partially funded by equipment for existing buildings.
Risks the call surfaced
Margin compression durability
HighFreight costs doubled to ₹20 Cr in Q2; energy/gas costs ₹1.8 Cr; management unable to pass through 100% of cost increases due to fixed contract constraints. Q2 PAT -6.6% QoQ despite 13% revenue growth signals pricing power limits.
Capacity utilization lag
MediumQ2 utilization 66% despite 40% revenue growth implies efficiency loss. Explained by product mix shift, new customer onboarding, and SKU expansion (140 → 152 products). Phase 1 building expected 80-85% utilization by FY29; Phase 2 at 50-60% Y1 startup. Risk of prolonged low utilization and ROI delay.
Export logistics and geopolitical risk
MediumExport revenue 70% of Q2 (up from 63% FY26). Logistics delays 30-60 days vs historical 25-30 days. Geopolitical sanctions on Chinese chemical players benefit Yasho, but duration uncertain. Shipping costs volatile; fuel surcharges unpredictable.
Customer concentration (unnamed MNC)
Medium₹150 Crores order book from unnamed MNC (NDA prevents disclosure). 15-year agreement provides duration, but customer concentration risk exists. Trial production Q4 FY27, commercialization Q1 FY28 — execution risk if trial fails.
Raw material price volatility and sourcing
Low10-15% raw material price increase in Q2 (March to September). Analyst noted 'unavailability of raw material because of the crisis.' Management says 'lot of challenges currently to procure the raw material, but that's okay. That's part of personal life.' Pricing power may not sustain if sourcing gets tighter.
Management
Score 6/10. Transparent on headwinds (freight, energy costs, logistics delays) but evasive on MNC contract scope due to NDA. Hedged on FY28 guidance ('>₹1,600 Cr' not a firm number). Downgraded EBITDA margin aspiration but acknowledged in Q&A. Met H1 growth expectations (89.7% YoY). Reaffirmed FY28 >₹1,600 Cr (raised from ₹1,500 Cr). Capex raised ₹125 Cr → ₹250 Cr, on track. But margin aspiration cut from 24% to 20-21%, signaling execution pressure.
1 · Q4 FY27
MNC contract trial production start; Pakhajan Phase 1 building commissioning outlook
2 · Q1 FY28
MNC contract commercialization (₹150 Cr order book); Phase 1 operations ramp
3 · H2 FY28+
Phase 2 building operational at 50-60% utilization; targeted 30-40% annual revenue growth; FY28 >₹1,600 Cr achievement
Long-term contract and capex expansion are credible catalysts, but near-term execution risk is material.
Informational and educational content only. Not investment advice.